Systemic corticosteroids have been a mainstay of treatment for noninfectious intermediate uveitis, posterior uveitis, and panuveitis, although their use is limited by well-known adverse effects. The addition of corticosteroid-sparing agents has been instrumental in controlling uveitis without the use of unsafe doses of corticosteroids.1 Although conventional immunosuppressive agents, such as methotrexate and mycophenolate mofetil, have been generally effective and well tolerated in patients with uveitis, the available treatment options for ocular inflammatory disease are still relatively limited. The advent of biologic therapy during the past decade has introduced a host of new and promising options for more specific, targeted immune therapy. One such biologic agent, adalimumab, is the only US Food and Drug Administration–approved noncorticosteroid treatment for noninfectious intermediate uveitis, posterior uveitis, and panuveitis and has been shown to reduce the risk of visual impairment and uveitis recurrence in these patients.2,3
Burkholder BM, Ramulu PY. Improving More Than Just Vision in Noninfectious Uveitis. JAMA Ophthalmol. 2017;135(6):518–519. doi:10.1001/jamaophthalmol.2017.0716
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: